8-K ·Filed Apr 21, 2026

VXRT

Vaxart, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001437749-26-012882
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor future filings for details on lease costs and any associated relocation expenses; the move may signal operational streamlining or cost management efforts.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
VXRT ▼ -33.18% at T+60d
NEUTRAL call ✗ call lost -33.18% · α vs SPY -40.08% · entry $0.7600 → $0.5078
Entry anchored
Apr 21, 2026
via day open
T+1d
-2.63%
call -2.63% · α -3.65%
$0.7400
settled 5mo ago
T+5d
+2.63%
call +2.63% · α +1.55%
$0.7800
settled 5mo ago
T+20d
-17.11%
call -17.11% · α -22.02%
$0.6300
settled 5mo ago
T+60d
-33.18%
call -33.18% · α -40.08%
$0.5078
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Vaxart, Inc. announced a lease amendment to expand its facilities by adding approximately 3,531 rentable square feet at Utah Avenue in South San Francisco, effective May 14, 2026, while terminating its lease at 170 Harbor Way, its current headquarters, effective May 15, 2026. This reflects a strategic relocation and consolidation of office space.

Key Facts

  • Vaxart entered into an amendment to lease an additional 3,531 rentable square feet at Utah Avenue, effective May 14, 2026.
  • The lease term for the additional space is 36 months.
  • The company is terminating its lease at 170 Harbor Way, its current headquarters, effective May 15, 2026.
  • The Harbor Way lease consists of approximately 24,606 rentable square feet.

Financial Impact

The financial impact is not quantified in the filing, but the company is relocating from a 24,606 sq ft headquarters to a smaller, expanded presence at Utah Avenue. The net change in leased space and cost implications are not disclosed.

operating expenseslease obligations

Risk Factors

  • Potential disruption from relocating headquarters.
  • Unspecified costs related to lease termination and new space setup.

Market Snapshot

Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-012882
Document: 0001437749-26-012882-index-headers.html0001437749-26-012882
Document: 0001437749-26-012882-index.html0001437749-26-012882
Document: 0001437749-26-012882.txt0001437749-26-012882
21 reports for VXRT
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +37.66%May 1, 2026
Filters
Rows
Reports for VXRT — sortable, filterable
TypeNow
Jul 28, 2026
9w ago
8-K
NEUTRAL ★ 2/10
$0.4800 $0.5000▲ +4.17%▲ +0.79%$0.4370 (−8.96%)
Jul 7, 2026
12w ago
8-K
NEUTRAL ★ 4/10
$0.5500 $0.6000▲ +9.09%▲ +5.93%$0.4370 (−20.55%)
Jul 6, 2026
12w ago
DEFA14A
NEUTRAL ★ 5/10
$0.6200 $0.5900▼ −4.84%▼ −5.69%$0.4370 (−29.52%)
Jul 2, 2026
13w ago
DEFA14A
BULLISH ★ 5/10
$0.6400 $0.5490▼ −14.22%▼ −14.52%$0.4370 (−31.72%)
Jul 2, 2026
13w ago
8-K
NEUTRAL ★ 4/10
$0.6400 $0.5200▼ −18.75%▼ −18.34%$0.4370 (−31.72%)
Jun 26, 2026
13w ago
DEFA14A
NEUTRAL ★ 4/10
$0.5700 $0.4501▼ −21.04%▼ −20.78%$0.4370 (−23.33%)
Jun 26, 2026
13w ago
DEFA14A
NEUTRAL ★ 3/10
$0.5700 $0.4501▼ −21.04%▼ −20.78%$0.4370 (−23.33%)
Jun 26, 2026
14w ago
8-K
MIXED ★ 5/10
$0.5700 $0.4501▼ −21.04%▼ −20.78%$0.4370 (−23.33%)
Jun 16, 2026
15w ago
DEFA14A
NEUTRAL ★ 3/10
$0.5600 $0.5300▼ −5.36%▼ −6.21%$0.4370 (−21.96%)
Jun 8, 2026
16w ago
DEFA14A
NEUTRAL ★ 4/10
$0.5800 $0.5502▼ −5.14%▼ −6.53%$0.4370 (−24.66%)
Showing 10 of 21

US Market Status

Market Closed — Opens Mon (64h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access